Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAVE long-term durvalumab safety and efficacy extension study
MOH_2020-01-20_008652Phase 4Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of durvalumab in melanoma, non-small cell lung cancer (NSCLC), transitional cell carcinoma (TCC) and 2 more (2 arms), sponsored by AstraZeneca. Primary endpoint: Long-term safety of durvalumab. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
melanomanon-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)renal cell carcinoma (RCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2020-01-20_008652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-01-20_008652.